Project Twenty21 receives new medical cannabis range

Project Twenty21 receives new medical cannabis range
© iStock/LPETTET

Project Twenty21 and LYPHE Group have created a partnership for a new range of medical cannabis products for the registry.

The partnership will see LYPHE Group’s EU-GMP NOIDECS range of cannabis products enter the UK market for the first time. The formulary of flowers and oils have been carefully curated from prescribing intelligence obtained from LYPHE’s clinics subsidiary, The Medical Cannabis Clinics and will now be provided on Europe’s largest patient-outcome registry, Project Twenty21.

Project Twenty21 is designed to deliver real change in the acceptance of cannabis among the medical fraternity, while increasing patient access across the UK, and is collecting a substantial evidence base on the efficacy and safety profile of medical cannabis across a range of conditions, which, when successful, will open the door for the NHS.

New products for the UK

LYPHE is a specialist in medical cannabis patient access with an operational ecosystem across clinics, dispensing, distribution, and education. The company presently treats more than 50% of all UK cannabis patients and the NOIDECS range becomes its first entrance into the pharmaceutical ‘Specials Medicines’ space.

Speaking about the new venture and partnership with Twenty21, Dean Friday, CEO of LYPHE said: “The supply of medical cannabis into the UK and most of Europe has been met with significant challenges. The supply chain has been slow and unreliable which can cause stress, anxiety, and significant risk to the health of patients.“By delivering a British range, NOIDECS can bring comfort to these patients, and indeed doctors nationwide, that there is now a reliable supply of these life-changing medicines. Twenty21 is the ideal launch pad for us to deliver safe and affordable patient access now, and expand access to more British patients into the future.”

David Badcock, CEO of Drug Science said of the partnership: “We are ecstatic to have LYPHE Group come onboard with us at such a critical time for patients. Patients have grown restless of the delays this industry has experienced and deserve access to safe and efficacious medical products. We are putting this right, and by adding the NOIDECS British-designed medical cannabis range to our existing formulary, it is absolutely the catalyst to this change.”

Patients and doctors can sign up to Twenty21 by visiting the website:, and visit the medical cannabis clinics via

Subscribe to our newsletter



Please enter your comment!
Please enter your name here